The FDA has granted a priority review designation to a new drug application (NDA) for capmatinib (INC280) for use as treatment for newly diagnosed and previously treated patients with locally advanced or metastatic MET
exon14 skipping (MET
ex14)—mutated non–small cell lung cancer (NSCLC).1
ex14—mutated non–small cell lung cancer.
- Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review. Published February 11, 2020. https://bit.ly/31L00cF. Accessed February 11, 2020.
- Wolf J, Setons T, Han J-Y, et al. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase II GEOMETRY mono-1 study. J Clin Oncol. 2019;37(suppl; abstr 9004). doi: 10.1200/JCO.2019.37.15_suppl.9004.
... to read the full story